Virtual Library
Start Your Search
J.B. Auliac
Author of
-
+
P3.02a - Poster Session with Presenters Present (ID 470)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02a-004 - NSCLC Patients Harboring ALK Translocation: Clinical Characteristics and Management in Real World Setting. EXPLORE GFPC 02-14 (ID 5043)
14:30 - 14:30 | Author(s): J.B. Auliac
- Abstract
Background:
ALK (Anaplastic Lymphoma Kinase) translocation is a rare oncogenic driver in NSCLC (Non Small Cell Lung Cancer) (3 to 5%) and few data are published on the management of these patients outside patients included in clinical trial. objective:to investigate clinical characteristics and management of these patients in real world setting.
Methods:
inclusion of patients with a diagnosis of NSCLC harboring ALK translocations between January 2012 and December 2014, collection of demographic and clinical characteristics, risk factors, Progression free survival (PFS), Overall Survival (OS), mode of progression and therapeutic management
Results:
132 patients recruited in 31 centers: 67(51%) men; age: 60.1 ± 14,5 years; PS 0/1 at diagnosis: 89%; non smokers:79%, adenocarcinoma: 93%; Stage at diagnosis 4/3/2-1:74%/19%/7%: co-mutations EGFR n=2, BRAF n=2, KRAS = 1, HER2 = 1. Outcomes of stage IV (n=97): first line treatment: chemotherapy: 75%, Best supportive care (BSC): 1 %, anti ALK: 24 %; response rate, disease control rate (DCR) and PFS to first line treatment: 42 %,64% and 7.5 months (CI 5.9 ;9.5), second line treatment (n=60): chemotherapy: 25%, anti BRAF 72%, BSC 3 %; response rate, DCR and PFS to second line treatment: 43.4%,70% and 4,7 months (CI 4.0; 8.1); 2 years-OS: 56.7% (CI 45.5 ;70.4), mediane OS was not reach.
Conclusion:
In this real world analysis, the majority of NSCLC patients with ALK translocation were non smokers,adenocarcinoma and appears to have a better survival to NSCLC pts without oncogenic driver. Clinical trial information: Supported by an academic grant from Lilly, Astra Zeneca, boehringer ingelheim
-
+
P3.02b - Poster Session with Presenters Present (ID 494)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02b-127 - NSCLC Patients Harboring HER2 Mutation: Clinical Characteristics and Management in Real World Setting. EXPLORE GFPC 02-14 (ID 4629)
14:30 - 14:30 | Author(s): J.B. Auliac
- Abstract
Background:
HER 2 (Human epidermal growth factor 2) mutation (exon-20 insertion) is a rare oncogenic driver in Non Small Cell Lung Cancer (NSCLC) (1%) and few data are published on the management of these patients outside patients included in clinical trial. Objective: to investigate clinical characteristics and management of these patients in real world setting
Methods:
multicentric inclusion of pts with a diagnosis of NSCLC harboring HER 2 mutations between January 2012 and December 2014, collection of demographic and clinical characteristics, risk factors, Progression free survival (PFS), Overall Survival (OS), mode of progression and therapeutic management
Results:
30 patients recruited in 17 centers: 20 (66,6%) female; age: 65,2 ± 12,1 years; PS 0/1 at diagnosis: 92,5 %; current/former smokers: 0/8(27,6%); adenocarcinoma: 93,3%; Stage at diagnosis 4-3/2-1: 93.1%/6,9%: co-mutations ALK n=1, RET n=1. Two-years overall survival (OS) 44,0% [CI :27,1 ; 71,5%] (early stage : 2-years OS : 100%). Management and Outcomes of stage IV (n=22): 82% received a first line platin based doublets With an overall response rate (ORR) and Progression Free Survival (PFS) of 61,5%, and 6.7 months (CI 5.6 ;19.0); 55% received a . second line treatment with an ORR and PFS of 36,4% and 3,4 months (CI 1,8;12,7); Two-years-OS was 27,2 %(CI:11,7;63,2%) and median OS survival 10,7 months (CI not research). .
Conclusion:
In this real world analysis, the majority of NSCLC patients with HER2 mutation were women, nonsmokers, adenocarcinoma and appears to have a same survival that NSCLC patients without oncogenic driver. Clinical trial information: Supported by an academic grant from Lilly, Astra Zeneca, boehringer ingelheim